Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1632
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18343437 | Treatment for Intraocular Pressure Related Disorders | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18060322 | SUBSTRATES AND BIOREACTORS FOR PREPARING A COMESTIBLE MEAT PRODUCT | Non-Final OA | Upside Foods, Inc. |
| 18186746 | METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV2.5 VECTOR | Final Rejection | The University of North Carolina at Chapel Hill |
| 17219430 | PLURIPOTENT STEM CELL FOR TREATMENT OF CEREBRAL INFARCTION | Non-Final OA | TOHOKU UNIVERSITY |
| 18167285 | METHOD FOR INDUCING EXTRACELLULAR TRAP (ET) FORMATION | Final Rejection | Université Paris Cité |
| 17540121 | RAAV-GUANYLATE CYCLASE COMPOSITIONS AND METHODS FOR TREATING LEBER'S CONGENITAL AMAUROSIS-1 (LCA1) | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18349566 | SKELETAL MUSCLE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 16992362 | THREE-DIMENSIONAL DIFFERENTIATION OF EPIBLAST SPHEROIDS TO KIDNEY ORGANOIDS MODELS STAGE-SPECIFIC EPITHELIAL PHYSIOLOGY, MORPHOGENESIS, AND DISEASE | Final Rejection | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 18261319 | MODULATION OF CHITINASE PROTEIN EXPRESSION | Non-Final OA | Dignity Health |
| 17822245 | TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3 | Non-Final OA | Yale University |
| 17845461 | COMPOSITION AND METHODS FOR CULTURING RETINAL PROGENITOR CELLS | Final Rejection | Yale University |
| 17930558 | SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 18361584 | METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES | Non-Final OA | Agilent Technologies, Inc. |
| 17783167 | GENE THERAPY COMPOSITION AND TREATMENT FOR MYH7-LINKED CARDIOMYOPATHY | Final Rejection | UCL BUSINESS LTD |
| 18182664 | Treatment of Neuronal Absence Disease by Transdifferentiating Treatment | Non-Final OA | Shanghai GeneMagic BioSciences Co., Ltd. |
| 18262588 | LARGE APERTURE-BASED TISSUE ENGINEERING SCAFFOLD AND USE THEREOF | Non-Final OA | SHANGHAI RESTHETIC BIO CO., LTD |
| 17044957 | MICROORGANISM SEPARATION AND DETECTION | Final Rejection | Momentum Bioscience Limited |
| 18209857 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, CONTAINING, AS ACTIVE INGREDIENT STEM CELLS OVEREXPRESSING SOD3 | Non-Final OA | Kangstem Biotech Co., Ltd. |
| 17614303 | COMPOSITIONS AND USE OF ENGINEERED MYOGENIC CELLS | Final Rejection | Institute of Zoology, Chinese Academy of Sciences |
| 18184017 | PRECISE BREEDING METHODS FOR GENE-EDITED NON-HUMAN ANIMALS | Final Rejection | Agricultural Technology Research Institute |
| 18043021 | FUSION PROTEIN ENHANCING CELL THERAPY | Final Rejection | Innovative Cellular Therapeutics Inc. |
| 18110400 | CELL MEDIUM FORMULATION FOR CELL STABILIZATION | Non-Final OA | AxoSim, Inc. |
| 18161543 | STEM CELLS FOR TRANSPLANTATION AND MANUFACTURING METHOD THEREFOR | Final Rejection | National Center of Neurology and Psychiatry |
| 16969523 | Cell Mass Fusion Method | Non-Final OA | Public University Corporation Yokohama City University |
| 17965257 | CUSTOM AUTOLOGOUS VACCINE COMPOSITION, AND A METHOD FOR ITS MANUFACTURE | Final Rejection | Athergen, Inc. |
| 17689643 | COMBINATION IMMUNOTHERAPY APPROACH FOR TREATMENT OF CANCER | Final Rejection | CALIDI BIOTHERAPEUTICS (NEVADA), INC. |
| 17942918 | TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES | Final Rejection | Ospedale San Raffaele srl |
| 17848320 | COMBINATORIAL CANCER IMMUNOTHERAPY | Final Rejection | Senti Biosciences, Inc. |
| 17709136 | NEURAL ORGANOID COMPOSITION AND METHODS OF USE | Final Rejection | Rene ANAND |
| 17290662 | COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS | Non-Final OA | AXOLOTL BIOLOGIX, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy